

Francesc Graus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6666207/publications.pdf>

Version: 2024-02-01

141
papers

21,803
citations

17440

63
h-index

13771

129
g-index

144
all docs

144
docs citations

144
times ranked

10940
citing authors

#	ARTICLE	IF	CITATIONS
1	A clinical approach to diagnosis of autoimmune encephalitis. <i>Lancet Neurology</i> , The, 2016, 15, 391-404.	10.2	2,782
2	Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 157-165.	10.2	2,382
3	Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. <i>Lancet Neurology</i> , The, 2010, 9, 776-785.	10.2	947
4	Antibody-Mediated Encephalitis. <i>New England Journal of Medicine</i> , 2018, 378, 840-851.	27.0	812
5	Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. <i>Lancet Neurology</i> , The, 2010, 9, 67-76.	10.2	805
6	Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. <i>Lancet Neurology</i> , The, 2014, 13, 167-177.	10.2	758
7	AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. <i>Annals of Neurology</i> , 2009, 65, 424-434.	5.3	712
8	Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. <i>Lancet Neurology</i> , The, 2014, 13, 276-286.	10.2	525
9	An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. <i>Lancet Neurology</i> , The, 2019, 18, 1045-1057.	10.2	497
10	A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. <i>Lancet Neurology</i> , The, 2014, 13, 575-586.	10.2	436
11	Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System. <i>Physiological Reviews</i> , 2017, 97, 839-887.	28.8	428
12	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. <i>Lancet Neurology</i> , The, 2018, 17, 760-772.	10.2	422
13	Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. <i>Brain</i> , 2015, 138, 94-109.	7.6	391
14	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology</i> , The, 2015, 16, e322-e332.	10.7	340
15	Antibodies and neuronal autoimmune disorders of the CNS. <i>Journal of Neurology</i> , 2010, 257, 509-517.	3.6	338
16	The clinical spectrum of Caspr2 antibody-associated disease. <i>Neurology</i> , 2016, 87, 521-528.	1.1	327
17	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	313
18	Encephalitis and AMPA receptor antibodies. <i>Neurology</i> , 2015, 84, 2403-2412.	1.1	311

#	ARTICLE	IF	CITATIONS
19	Encephalitis and antibodies to dipeptidylâ€‘peptidaseâ€‘like proteinâ€‘6, a subunit of Kv4.2 potassium channels. <i>Annals of Neurology</i> , 2013, 73, 120-128.	5.3	305
20	Clinical manifestations of the anti-IgLON5 disease. <i>Neurology</i> , 2017, 88, 1736-1743.	1.1	300
21	Anti-LGI1â€‘associated cognitive impairment. <i>Neurology</i> , 2016, 87, 759-765.	1.1	264
22	Investigations in GABA _A receptor antibody-associated encephalitis. <i>Neurology</i> , 2017, 88, 1012-1020.	1.1	257
23	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. <i>Multiple Sclerosis Journal</i> , 2015, 21, 866-874.	3.0	241
24	Autoimmune postâ€‘herpes simplex encephalitis of adults and teenagers. <i>Neurology</i> , 2015, 85, 1736-1743.	1.1	226
25	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , The, 2020, 19, 234-246.	10.2	207
26	Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 535-548.	27.6	186
27	A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. <i>Neurology</i> , 2019, 92, e244-e252.	1.1	183
28	Neuropathological criteria of anti-IgLON5-related tauopathy. <i>Acta Neuropathologica</i> , 2016, 132, 531-543.	7.7	173
29	DPPX antibodyâ€‘associated encephalitis. <i>Neurology</i> , 2017, 88, 1340-1348.	1.1	170
30	Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. <i>JAMA Neurology</i> , 2015, 72, 874.	9.0	169
31	Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. <i>Cancer</i> , 1995, 75, 99-109.	4.1	159
32	Cerebellar Ataxia and Glutamic Acid Decarboxylase Antibodies. <i>JAMA Neurology</i> , 2014, 71, 1009.	9.0	154
33	Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. <i>JAMA Neurology</i> , 2016, 73, 417.	9.0	152
34	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy. <i>Nature Communications</i> , 2019, 10, 2416.	12.8	150
35	Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. <i>Blood</i> , 2014, 123, 3230-3238.	1.4	145
36	Investigations on CXCL13 in Antiâ€‘<i>N</i>-Methyl-<sc>D</sc>-Aspartate Receptor Encephalitis. <i>JAMA Neurology</i> , 2015, 72, 180.	9.0	142

#	ARTICLE	IF	CITATIONS
37	Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. <i>Annals of Neurology</i> , 1998, 44, 976-980.	5.3	140
38	Paraneoplastic neurological syndromes. <i>Current Opinion in Neurology</i> , 2012, 25, 795-801.	3.6	139
39	Encephalitis with mGluR5 antibodies. <i>Neurology</i> , 2018, 90, e1964-e1972.	1.1	139
40	Clinical and Immunologic Investigations in Patients With Stiff-Person Spectrum Disorder. <i>JAMA Neurology</i> , 2016, 73, 714.	9.0	135
41	Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. <i>Annals of Neurology</i> , 2016, 80, 388-400.	5.3	134
42	GAD antibodies in neurological disorders – insights and challenges. <i>Nature Reviews Neurology</i> , 2020, 16, 353-365.	10.1	134
43	Randomized Placebo-Controlled Phase II Trial of Autologous Mesenchymal Stem Cells in Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e113936.	2.5	131
44	Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. <i>Clinical Cancer Research</i> , 2018, 24, 2812-2819.	7.0	128
45	Antibodies to Inhibitory Synaptic Proteins in Neurological Syndromes Associated with Glutamic Acid Decarboxylase Autoimmunity. <i>PLoS ONE</i> , 2015, 10, e0121364.	2.5	127
46	Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. <i>Neurology</i> , 2018, 90, e1386-e1394.	1.1	120
47	Antibodies to Aquaporin 4, Myelin-Oligodendrocyte Glycoprotein, and the Glycine Receptor $\alpha 1$ Subunit in Patients With Isolated Optic Neuritis. <i>JAMA Neurology</i> , 2015, 72, 187.	9.0	119
48	Human neurexin-3 antibodies associate with encephalitis and alter synapse development. <i>Neurology</i> , 2016, 86, 2235-2242.	1.1	116
49	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. <i>Journal of Neurology</i> , 2016, 263, 1349-1360.	3.6	112
50	Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. <i>Annals of Neurology</i> , 1999, 46, 774-777.	5.3	103
51	Metabotropic Glutamate Receptor Type 1 Autoantibody-Associated Cerebellitis. <i>Archives of Neurology</i> , 2010, 67, 627-30.	4.5	99
52	Antibody-associated CNS syndromes without signs of inflammation in the elderly. <i>Neurology</i> , 2017, 89, 1471-1475.	1.1	97
53	Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. <i>Journal of Neuroinflammation</i> , 2016, 13, 226.	7.2	94
54	Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. <i>Neurology</i> , 2020, 94, e2302-e2310.	1.1	94

#	ARTICLE	IF	CITATIONS
55	Hashimoto encephalopathy in the 21st century. <i>Neurology</i> , 2020, 94, e217-e224.	1.1	92
56	An antineuronal autoantibody in paraneoplastic opsoclonus. <i>Annals of Neurology</i> , 1988, 23, 528-531.	5.3	87
57	Chorea and related movement disorders of paraneoplastic origin: the PNS EuroNetwork experience. <i>Journal of Neurology</i> , 2011, 258, 2058-2068.	3.6	81
58	Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. <i>Neuro-Oncology</i> , 2013, 15, 797-805.	1.2	77
59	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1843-1851.	3.0	77
60	Epilepsia partialis continua: A new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. <i>Annals of Neurology</i> , 1999, 45, 255-258.	5.3	72
61	Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1753-1759.	3.0	71
62	Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e60438.	2.5	70
63	Increased CSF levels of IL-1 β , IL-6, and ACE in SARS-CoV-2-associated encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	69
64	Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. <i>Epilepsy Research</i> , 2017, 129, 101-105.	1.6	67
65	Stiff-leg syndrome: A focal form of stiff-man syndrome. <i>Annals of Neurology</i> , 1998, 43, 400-403.	5.3	62
66	Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e136.	6.0	62
67	Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. <i>Annals of Neurology</i> , 2020, 88, 1023-1027.	5.3	61
68	Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. <i>Neurology</i> , 2020, 95, e3012-e3025.	1.1	60
69	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2014, 71, 74.	9.0	59
70	HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	55
71	Clinical significance of Kelch-like protein 11 antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	54
72	Clinical, Neuroimmunologic, and CSF Investigations in First Episode Psychosis. <i>Neurology</i> , 2021, 97, e61-e75.	1.1	54

#	ARTICLE	IF	CITATIONS
73	A novel treatmentâ€responsive encephalitis with frequent opsoclonus and teratoma. <i>Annals of Neurology</i> , 2014, 75, 435-441.	5.3	51
74	Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. <i>Neurology</i> , 2021, 97, .	1.1	50
75	IgLON5 autoimmunity and abnormal behaviours during sleep. <i>Lancet, The</i> , 2015, 385, 1590.	13.7	49
76	Paraneoplastic neuropathies. <i>Current Opinion in Neurology</i> , 2013, 26, 489-495.	3.6	48
77	Sleep disorders in anti-NMDAR encephalitis. <i>Neurology</i> , 2020, 95, e671-e684.	1.1	47
78	Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis. <i>Frontiers in Immunology</i> , 2021, 12, 691536.	4.8	46
79	Late-onset neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	44
80	Anti-IgLON5 disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	43
81	The Sleep Disorder in Anti-IgLON5 Disease. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 41.	4.2	42
82	Normal proprioceptive trigeminal afferents in patients with SjÃ¶rgren's syndrome and sensory neuronopathy. <i>Annals of Neurology</i> , 1990, 28, 786-790.	5.3	40
83	Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	39
84	Paraneoplastic neurological syndromes: diagnosis and treatment. <i>Current Opinion in Internal Medicine</i> , 2008, 7, 82-87.	1.5	36
85	Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 564-568.	3.0	36
86	Seizure-related 6 homolog like 2 autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	36
87	Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature. <i>Neuro-Oncology</i> , 2016, 18, 707-715.	1.2	35
88	Neuropathological Variability within a Spectrum of <sc>NMDAR</sc>â€Encephalitis. <i>Annals of Neurology</i> , 2021, 90, 725-737.	5.3	35
89	Pregnancy outcomes in anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	30
90	Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e659.	6.0	30

#	ARTICLE	IF	CITATIONS
91	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	29
92	Incidence and Impact of COVID-19 in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	29
93	Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. <i>Neurology</i> , 2017, 88, 1235-1242.	1.1	28
94	Thymoma and Autoimmune Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	28
95	Pitfalls in the detection of CV2 (CRMP5) antibodies. <i>Journal of Neuroimmunology</i> , 2016, 290, 80-83.	2.3	27
96	Opsoclonusâ€“myoclonus syndrome and limbic encephalitis associated with GABAB receptor antibodies in CSF. <i>Journal of Neuroimmunology</i> , 2014, 272, 91-93.	2.3	26
97	Encephalitis with Autoantibodies against the Glutamate Kainate Receptors <scp>GluK2</scp>. <i>Annals of Neurology</i> , 2021, 90, 101-117.	5.3	26
98	Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e68.	6.0	25
99	Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis â€“ Authors' reply. <i>Lancet Neurology</i> , The, 2016, 15, 1010.	10.2	25
100	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. <i>Neurology</i> , 2022, 98, .	1.1	25
101	Voltage-gated potassium channel antibodies. <i>Neurology</i> , 2016, 86, 1657-1658.	1.1	22
102	Cognitive and brain structural changes in long-term oligodendroglial tumor survivors. <i>Neuro-Oncology</i> , 2019, 21, 1470-1479.	1.2	22
103	Neuropathologic features of anti-dipeptidyl-peptidase-like protein-6 antibody encephalitis. <i>Neurology</i> , 2015, 84, 430-432.	1.1	20
104	No evidence of CNS infection with <i>Chlamydia pneumoniae</i> in patients with multiple sclerosis. <i>Journal of Neurology</i> , 2001, 248, 617-618.	3.6	19
105	Understanding anti-IgLON5 disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e393.	6.0	19
106	Imaging spectrum of central nervous system complications of hematopoietic stem cell and solid organ transplantation.. <i>Neuroradiology</i> , 2017, 59, 105-126.	2.2	18
107	Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. <i>Muscle and Nerve</i> , 2017, 56, E162-E167.	2.2	18
108	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 230-234.	2.0	18

#	ARTICLE	IF	CITATIONS
109	The impact of the introduction of the 14-3-3 protein assay in the surveillance of sporadic Creutzfeldt-Jakob disease in Catalonia. <i>Journal of Neurology</i> , 2001, 248, 592-594.	3.6	14
110	Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67). <i>Journal of Neuroimmunology</i> , 2016, 300, 15-17.	2.3	14
111	The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders. <i>Journal of Neuroimmunology</i> , 2019, 326, 14-18.	2.3	12
112	Hypoglycemic seizures and epilepsy in type I diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2014, 346, 307-309.	0.6	10
113	Autoimmune encephalitis with GABA A receptor antibodies in a 10-year-old girl. <i>Clinical Neurology and Neurosurgery</i> , 2018, 164, 160-163.	1.4	10
114	Autoimmune encephalitis or autoimmune psychosis?. <i>European Neuropsychopharmacology</i> , 2021, 50, 112-114.	0.7	9
115	Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome. <i>Neurology</i> , 2021, 96, e1082-e1087.	1.1	9
116	Does gender matter in glioblastoma?. <i>Clinical and Translational Oncology</i> , 2011, 13, 737-741.	2.4	8
117	Paraneoplastic stiff person syndrome with small cell carcinoma of the bladder and anti-Ri antibodies. <i>Clinical Neurology and Neurosurgery</i> , 2018, 173, 194-195.	1.4	7
118	Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination. <i>Journal of the Neurological Sciences</i> , 2015, 352, 127-128.	0.6	6
119	Antibody-mediated neuropsychiatric disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 37-40.	2.9	6
120	Pilot Study of the Effects of Chronic Intracerebroventricular Infusion of Human Anti-IgLON5 Disease Antibodies in Mice. <i>Cells</i> , 2022, 11, 1024.	4.1	6
121	Neuronal Antibodies in Creutzfeldt-Jakob Disease—Reply. <i>JAMA Neurology</i> , 2014, 71, 514.	9.0	5
122	Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?—Authors' reply. <i>Lancet Neurology</i> , The, 2014, 13, 864-865.	10.2	5
123	Towards a better recognition of paraneoplastic brainstem encephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1141-1141.	1.9	4
124	Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642210796.	3.5	4
125	Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma. <i>Journal of Neuroimmunology</i> , 2016, 297, 98-102.	2.3	3
126	State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. <i>Neurology and Therapy</i> , 2020, 9, 281-300.	3.2	3

#	ARTICLE	IF	CITATIONS
127	Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodiesâ€”Reply. JAMA Neurology, 2016, 73, 891.	9.0	2
128	Neuro-oncology: setting new standards of management. Lancet Neurology, The, 2006, 5, 8-9.	10.2	1
129	Vanishing spinal cord after varicella-zoster virus myelitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e364.	6.0	1
130	Antibodies to Neural Cell Surface Antigens. , 2022, , 135-166.		1
131	Pathogenesis and Disease Mechanisms in Neuronal Antibody-Mediated Encephalitis. , 2022, , 42-106.		1
132	Frequently Asked Questions on Autoimmune Encephalitis and Related Disorders. , 2022, , 630-655.		1
133	Purkinje cell antibodies in a patient with cerebellar disorder. Journal of Neurology, 1992, 239, 237-237.	3.6	0
134	Reply: Rapidly progressing diffuse Lewy body disease. Movement Disorders, 2011, 26, 2585-2585.	3.9	0
135	Autoimmune Cerebellar Ataxias. , 2022, , 342-367.		0
136	Autoimmune Brainstem Encephalitis. , 2022, , 368-390.		0
137	Deconstructing Hashimoto Encephalopathy. , 2022, , 460-475.		0
138	CNS Syndromes at the Frontier of Autoimmune Encephalitis. , 2022, , 476-502.		0
139	Seizures and Antibodies Against Surface Antigens. , 2022, , 255-289.		0
140	Limbic Encephalitis. , 2022, , 167-190.		0
141	General Approach to Diagnosis. , 2022, , 19-41.		0